PARIS (Reuters) - Sanofi on Tuesday announced it had reached an agreement with Janssen, a part of Johnson & Johnson, to develop and commercialize a vaccine candidate for extra-intestinal pathogenic E.coli.
Under the terms of the deal, both parties will co-fund current and future research and development costs. Sanofi will pay 5 million upfront to Janssen, followed by development and commercial milestones.
(Reporting by Tassilo Hummel; Editing by Benoit Van Overstraeten)
Copyright © 2023 Thomson Reuters
Recevez toutes les infos sur SANOFI en temps réel :
Par « push » sur votre mobile grâce à l’application BFM Bourse
Par email